Zydus Cadila gets tentative USFDA nod for capsules treating Parkinson disease

Zydus Cadila, a part of Cadila Healthcare, informed the bourses during the weekend that it has received tentative approval from United States Food and Drug Administration (USFDA) for Carbidopa and Levodopa extended-release capsules.

The company has received approval to market the above-mentioned medicines in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

This medicine is used in the treatment of Parkinson's disease, post-encephalitic Parkinsonism, and symptomatic Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

The group has 295 approvals presently and has so far, filed over 390 ANDAs to date, since the commencement of its filing process in FY 2003-04.

Talking about the company’s contribution to COVID-19 treatment, the company is putting all the efforts to combat the COVID-19 pandemic. Vaccine Technology Centre (VTC) of Zydus Cadila is capable of developing and manufacturing viral, toxoid, polysaccharide, conjugate, and others. Zydus was the first company in India to develop and indigenously manufacture the vaccine to combat the Swine Flu pandemic in 2010.

The company’s revenue mix comprised of US Formulations (49 per cent), India Formulations (28 per cent), EMB Formulations (7 per cent), Animal Health (6 per cent), Wellness (4 per cent), API (3 per cent), Alliances (1 per cent) and Europe Formulations (2 per cent).

Today, the stock of Cadila Healthcare gained nearly three per cent in early trade and made an intraday high of Rs 400.70 on BSE.